Nkarta (NASDAQ:NKTX) Price Target Raised to $11.00

Nkarta (NASDAQ:NKTX) had its target price upped by Needham & Company LLC from $10.00 to $11.00 in a report released on Thursday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

NKTX has been the subject of a number of other reports. Wall Street Zen upgraded shares of Nkarta from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Nkarta in a research note on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Nkarta currently has a consensus rating of “Hold” and a consensus price target of $12.00.

Nkarta Stock Down 3.7%

NKTX stock opened at $2.06 on Thursday. The business’s 50-day moving average price is $2.28 and its 200-day moving average price is $2.10. The stock has a market cap of $153.04 million, a P/E ratio of -1.47 and a beta of 0.47. Nkarta has a twelve month low of $1.42 and a twelve month high of $2.81.

Nkarta (NASDAQ:NKTX) last released its earnings results on Wednesday, March 25th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.05). On average, equities research analysts expect that Nkarta will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Nkarta news, CEO Paul J. Hastings sold 26,046 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $2.07, for a total value of $53,915.22. Following the completion of the transaction, the chief executive officer directly owned 390,023 shares in the company, valued at $807,347.61. This represents a 6.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 8.40% of the company’s stock.

Hedge Funds Weigh In On Nkarta

Several hedge funds have recently modified their holdings of the stock. GSK plc bought a new position in shares of Nkarta during the fourth quarter worth $5,829,000. Monaco Asset Management SAM increased its holdings in Nkarta by 29.2% in the 4th quarter. Monaco Asset Management SAM now owns 2,546,932 shares of the company’s stock valued at $4,712,000 after acquiring an additional 576,022 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Nkarta by 48.6% in the 4th quarter. Renaissance Technologies LLC now owns 1,702,022 shares of the company’s stock valued at $3,149,000 after acquiring an additional 556,945 shares during the last quarter. Geode Capital Management LLC lifted its stake in Nkarta by 0.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,208,378 shares of the company’s stock worth $2,006,000 after purchasing an additional 10,065 shares in the last quarter. Finally, State Street Corp lifted its stake in Nkarta by 1.9% in the 4th quarter. State Street Corp now owns 1,169,356 shares of the company’s stock worth $2,163,000 after purchasing an additional 21,241 shares in the last quarter. Hedge funds and other institutional investors own 80.54% of the company’s stock.

Nkarta News Summary

Here are the key news stories impacting Nkarta this week:

• Negative Sentiment: HC Wainwright reduced earnings estimates across multiple quarters and years (Q1–Q4 2026 and FY2026–2030), increasing expected per‑share losses (FY2026 now modeled at about ($1.74) vs prior ($1.50)). The firm also pushed out weaker EPS trajectories for FY2027–FY2030 — a signal of slower progress or higher cash burn expectations that can mean more dilution or funding needs for Nkarta. HC Wainwright estimate cuts
• Negative Sentiment: Wall Street Zen/covered outlet lowered its rating to “Sell,” adding independent downward pressure from sentiment and potentially reducing short‑term buyer interest. Rating downgrades can accelerate outflows in thinly traded small‑cap biotechs. Nkarta Lowered to “Sell” Rating

About Nkarta

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.